NCT01941654 is a Phase 2 clinical trial of preemptive local ablative therapy in NSCLC, sponsored by Chinese University of Hong Kong.

Who is sponsoring NCT01941654?

NCT01941654 is sponsored by Chinese University of Hong Kong.

What drugs are being tested in NCT01941654?

Interventions in NCT01941654: preemptive local ablative therapy, Oral TKI.

What condition does NCT01941654 study?

NCT01941654 studies NSCLC, Activating EGFR Mutation.

Is NCT01941654 still recruiting?

NCT01941654 is currently completed. Last updated 18 June 2020.

Last reviewed 2020-06-18 · How we verify

NCT01941654

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ATOM_local Ablative Therapy

Completed Phase 2 Last updated 18 June 2020

What this trial tests

Phase 2 trial testing preemptive local ablative therapy in NSCLC in 18 participants. Completed in 28 May 2020.

Timeline

18 September 2013

Primary endpoint
31 December 2017

28 May 2020

Quick facts

Lead sponsor	Chinese University of Hong Kong
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	18 September 2013
Primary completion	31 December 2017
Estimated completion	28 May 2020
Sites	1 location across Hong Kong

Drugs / interventions tested

preemptive local ablative therapy
Oral TKI

Conditions studied

NSCLC — all drugs for NSCLC →
Activating EGFR Mutation — all drugs for Activating EGFR Mutation →

Sponsor

Chinese University of Hong Kong

Who can join

18 and older, any sex, with NSCLC or Activating EGFR Mutation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine the efficacy of preemptive local ablative therapy in NSCLC patients with activating EGFR mutation who have oligometastatic residual metabolic-active disease after first-line EGFR TKI, as measured by PFS rate at 1 year from the trial enrollment.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Radical irradiation of extracranial oligometastases.
Salama JK, Milano MT. · · 2014 · cited 68× · PMID 25113765 · DOI 10.1200/jco.2014.55.9567
Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer.
Laurie SA, Banerji S, Blais N, Brule S, et al · · 2019 · cited 36× · PMID 30853813 · DOI 10.3747/co.26.4116
Risk factors and management of oligometastatic non-small cell lung cancer.
Patel AN, Simone CB, Jabbour SK. · · 2016 · cited 13× · PMID 27060187 · DOI 10.1177/1753465816642636
Local ablative radiotherapy for oligometastatic non-small cell lung cancer.
Suh YG, Cho J. · · 2019 · cited 11× · PMID 31591862 · DOI 10.3857/roj.2019.00514
Unexpected long survival of brain oligometastatic non-small cell lung cancer (NSCLC) treated with multimodal treatment: a single-center experience and review of the literature.
Onesti CE, Iacono D, Angelini S, Lauro S, et al · · 2016 · cited 8× · PMID 28149766 · DOI 10.21037/tlcr.2016.09.01
Thoracic intervention and surgery to cure lung cancer: an overview of stereotactic ablative radiotherapy in early and oligometastatic lung cancer.
Chia B, Landau D, Hanna G, Conibear J. · · 2019 · cited 6× · PMID 29672204 · DOI 10.1177/0141076818763334
Insights on Oligometastatic Non-Small-Cell Lung Cancer.
Valdivia A, Mascaro-Baselga P, Salva-de Torres C, Geng-Cahuayme A, et al · · 2025 · PMID 40805152 · DOI 10.3390/cancers17152451
Current Status of Multimodal Therapy for Oligometastatic Disease, Induced Oligometastatic Disease, and Oligo-Progressive Disease in <i>EGFR</i>-Mutated Non-Small-Cell Lung Cancer.
Miyawaki T, Kenmotsu H, Ko R, Oshima M, et al · · 2025 · PMID 40647500 · DOI 10.3390/cancers17132202

Verify or expand the search:

Other recruiting trials for NSCLC

Currently open trials in the same condition.

NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
NCT07274813 — A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors · EARLY_PHASE1 · recruiting
NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
NCT07169552 — HC010 in First-line PD-L1 Positive Advanced NSCLC Patients · Phase 2 · recruiting

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01941654 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
Last refreshed: 18 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01941654.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing